Kare Schultz earned $107m during Teva tenure
Former Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) CEO Kåre Schultz earned $107 million during his term as head of the Israeli company between December 2017 and the end of 2022. During 2022 his…